South Korea · Delayed Price · Currency is KRW CJ Cheiljedang Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw sales growth across food, BIO, and logistics, but operating profit declined due to BIO price pressures. Q2 is expected to bring improved profitability, especially in BIO, with continued sales growth and margin recovery amid ongoing global expansion and cost challenges.
Fiscal Year 2025
-
Q4 2025 saw modest sales growth but a sharp drop in operating profit due to Bio business weakness and holiday timing. Global Food outperformed, while Bio faced intense competition and pricing pressure. 2026 guidance projects low single-digit sales growth and stable margins.
-
Q3 2025 saw a 1.9% year-over-year revenue decline (excluding logistics) due to bio and feed & care weakness, while food business showed resilience and global expansion. Operating profit and net profit dropped sharply, with ongoing margin pressure in bio and cost headwinds in food.
-
Q2 2025 saw flat sales overall, with overseas food and bio growth offsetting domestic food weakness. Net profit rose 40% year-over-year, while operating profit declined due to higher costs and weak Korean demand. Q3 guidance projects low single-digit revenue growth and stable margins.
-
Q1 2025 saw overseas food sales growth and strong online expansion, but overall sales and OP declined due to bio and FNC setbacks and high raw material costs. Bio segment benefited from anti-dumping duties, while logistics and feed/care showed mixed results. Q2 sales growth is projected in the low to mid single digits.
Fiscal Year 2024
-
Q4 operating profit rose year-over-year, led by BIO and Feed & Care, but net profit was negative due to asset impairments. Food and BIO segments saw growth, while U.S. food faced short-term supply disruptions. Dividend payout and CapEx guidance were raised for 2025.
-
Q3 2024 saw modest OP growth as global and bio segments offset declines in Korea. Online food sales surged, while bio and logistics units delivered strong profit gains. Q4 outlook is positive, with expected sales and OP margin improvements driven by new products and market expansion.
-
Q2 2024 saw 14% OP growth, led by high-margin bio products and improved Feed and Care margins, despite a slight sales decline in food. U.S. and Europe drove global growth, while Korea faced weak consumer demand. Q3 is expected to see low single-digit sales growth and 6%-7% OP.